Understanding why people combine drugs requires listening to their accounts without treating those accounts as proof that the combination works as intended. A multi-site qualitative study documented reasons for stimulant–opioid co-use in rural U.S. settings, including methamphetamine use intended to increase energy, offset unwanted opioid effects or respond to tolerance.
The interviews are evidence about experiences, beliefs and circumstances. They were not controlled tests of pharmacological “balance,” overdose reversal or improved functional performance.
When and where were the interviews conducted?
Fredericksen and colleagues analyzed interviews collected in 2018–2019 through the Rural Opioid Initiative. The study covered eight sites spanning ten states and 65 counties. The article was published in 2024; the accounts describe an earlier drug-market context, not a verified picture of conditions in 2026.
Participants were recruited through community programs, service providers and, at some sites, outreach. Eligibility and recruitment details varied by site. The sample was not a probability sample of all rural residents or everyone who used methamphetamine.
Researchers conducted 60–90-minute semi-structured interviews and used an iterative coding process, with independent coding and reconciliation of differences. They coded 1,672 excerpts from 349 interviews. Excerpts are units of text, not additional independent people.
What did the reported denominators mean?
Of the 349 interviewees, 137 discussed current stimulant use in the context of opioid use, reported as 39%. Within that subgroup, methamphetamine was mentioned by 78% and cocaine or crack by 26%.
The percentages concern a selected interview subgroup and are not mutually exclusive drug categories. They cannot be read as the prevalence of methamphetamine use among rural Americans, nor as a national estimate of simultaneous mixing.
The guide focused heavily on opioid use and injection. It did not systematically characterize all current non-injection stimulant use. Not discussing a behavior in this interview framework is therefore not equivalent to a standardized negative assessment of that behavior.
Which motivations emerged?
The researchers identified four broad themes. Participants described changing availability and cost; pursuit of particular combined or stronger effects; attempts to manage unwanted effects or withdrawal; and functional goals such as maintaining energy for daily work while reducing pain.
Some accounts linked adding a stimulant to reduced desired effects after repeated opioid use. These were participants’ descriptions of tolerance and their responses to it, not laboratory confirmation of an opioid tolerance mechanism or measured changes in receptor sensitivity.
Other accounts emphasized economic pressure and physically demanding work. Those narratives help explain why a person might perceive methamphetamine as useful. They do not demonstrate improved accuracy, judgment, safety or sustained productivity.
Did “concurrent” always mean simultaneous?
No. The study included accounts of simultaneous use and of using the drugs sequentially within a relatively short period. Investigators did not systematically probe exact use times, and acknowledged that their treatment of concurrent use was necessarily simplified.
The interviews therefore cannot establish a precise interval, dose, route or toxicological interaction for every account. A positive test for two drugs would require its own interpretation; it could not resolve those missing details by reference to this qualitative study.
The descriptions also should not be converted into instructions for reproducing the combinations. Their research value lies in explaining motivations and context.
Did the study show that methamphetamine reverses opioid overdose?
No. Some participants believed a stimulant could avert or reverse an opioid overdose, and the authors identified that belief as an important finding. The interviews did not include controlled overdose-reversal testing, verified dosing, continuous respiratory measurements or an adjudicated comparison of outcomes.
Current CDC guidance on polysubstance use states that stimulant and depressant effects do not simply neutralize each other and may mask effects. A person’s report of feeling more awake is therefore not proof that an opioid-related respiratory hazard has resolved.
For a suspected overdose, CDC guidance calls for an opioid-overdose reversal medication such as naloxone when available and emergency assistance. Methamphetamine should not be treated as an evidence-based substitute on the strength of these interviews. This safety context is separate from the historical study’s findings.
What are the study’s main limitations?
Self-report, selective recruitment, variable site criteria and an opioid/injection-centered interview guide limit generalization. The study did not estimate causal effects of co-use on overdose, measure blood drug concentrations or test whether perceived functional benefits were objectively present.
The authors also noted limited racial and ethnic diversity and the early timing of data collection relative to later changes in the drug supply. Descriptions of access, cost and treatment barriers are historically situated accounts rather than current market measurements.
Qualitative evidence remains useful within those limits. It can reveal reasons that a toxicology result alone cannot supply and guide better questions about exposure history, perceived benefits and barriers to care. It cannot determine an individual’s intent or validate the physiological explanation they give.
Scientific source and safety context
Fredericksen RJ, Baker R, Sibley A, et al. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry. Harm Reduction Journal. 2024;21:74. doi:10.1186/s12954-024-00986-z. Full text. Original qualitative human research using historical 2018–2019 interviews.
Safety context: CDC, Polysubstance Use Facts and Naloxone Frequently Asked Questions, checked October 29, 2026.
Leave a Reply